Search results

Learn the differences between pre-money and post-money valuations for private companies and how to calculate preferred share price when pitching investors during a priced round.

Health and biotech VC fundraising surged in the aftermath of the COVID-19 pandemic and has stood strong against market headwinds.

After two-plus years of steady declines, the Series C market may be bouncing back.

At Series D and later, VC deal activity slowed down in Q1 2024. There are reasons for the decline on both sides of the negotiating table.

The venture capital fundraising market remained slow in Q1 2024, but valuations held steady or climbed at almost every stage.

Our experts walk through what you need to know about 409A valuations and how to prepare for a successful valuations audit.

An increasing number of seed-stage rounds are extension financings, or bridge rounds.

Valuations and round sizes rose at most stages in Q1 2024.

As the count of new seed deals steadily shrinks, some founders are finding new funding paths.

Valuation step-up multiples trended up last year at Series A and Series B. Series C was a different story.

Last year’s figures in late-stage dealmaking were far off the late-stage market’s peak in 2021. They’re also still lagging behind the pre-pandemic funding market of 2019.